Incidence and impact of resistance against approved antiretroviral drugs.
about
Analysis of HIV-1 drug resistant mutations by line probe assay and direct sequencing in a cohort of therapy naive HIV-1 infected Italian patientsStructure of the Antiviral Assembly Inhibitor CAP-1 Complex with the HIV-1 CA ProteinA randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: the UK-Vanguard StudyEffects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART studyAntiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study.In vivo toxicity, pharmacokinetics, and anti-human immunodeficiency virus activity of stavudine-5'-(p-bromophenyl methoxyalaninyl phosphate) (stampidine) in mice.In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.Ongoing trials of immune-based therapies for HIV infection in adults.Molecular techniques should now replace cell culture in diagnostic virology laboratories.Molecular techniques should not now replace cell culture in diagnostic virology laboratories.Mechanistic aspects of HIV-1 reverse transcription initiation.Structure-based design and engineering of a nontoxic recombinant pokeweed antiviral protein with potent anti-human immunodeficiency virus activityProtein-protein interactions as targets for antiviral chemotherapy.Considerations and development of topical microbicides to inhibit the sexual transmission of HIV.In vivo antiretroviral activity of stampidine in chronically feline immunodeficiency virus-infected catsSynthesis and evaluation of 3'-azido-2',3'-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus.The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets.Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.Structural probing of the HIV-1 polypurine tract RNA:DNA hybrid using classic nucleic acid ligands.Enhanced antibody responses elicited by a CpG adjuvant do not improve the protective effect of an aldrithiol-2-inactivated simian immunodeficiency virus therapeutic AIDS vaccine.Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequenciesIdentification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors.Adaptive HIV-1 evolutionary trajectories are constrained by protein stability.Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1Development and automation of a 384-well cell fusion assay to identify inhibitors of CCR5/CD4-mediated HIV virus entry.Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naïve individuals.HIV antiviral drug resistance: patient comprehension.Antiretroviral drug resistance among HIV-1 infected children failing treatment.Immunological and virological consequences of patient-directed antiretroviral therapy interruption during chronic HIV-1 infection.Increasing prevalence of resistance mutations in antiretroviral-naïve individuals with established HIV-1 infection from 1996-2001 in St. Louis.
P2860
Q24795766-48423B96-0110-4542-9D2E-DEAA8F82726DQ27647971-14459610-8F5E-4496-B793-71C78637C5ACQ28469017-C07A4350-7C55-48EA-8203-72ED397E3146Q33534648-F4AF3616-7086-4BE4-88FF-1D8462011DF3Q34112020-6A520F2A-56ED-404F-B166-A5CFDC75CB9AQ34141998-FE533160-EA5F-414C-AC87-C5AAEA1F51AAQ34352006-E8DA791D-E72A-418D-9DF5-6D06FAE5F9E9Q34451967-2F9F4EB6-5824-43C8-9761-22CF2A562731Q34464937-03DE2A15-047C-4E39-A198-D9B1E356234EQ34464943-05862BAE-4A48-4920-BFA8-111B30E18458Q34490256-AADA6EB6-AD76-42E1-8D6F-62B2AE45AB63Q34734416-C0A571B3-BD44-4B5C-887D-22335FFAFF60Q34747522-C90584B8-4F4A-4F6B-8CF3-46BCCCFBC0C5Q34768558-DAA67579-247C-49AF-928B-21CADF8C1F04Q34883567-4EF0D522-318A-4A05-AB40-008013DFC9A5Q34952588-19244883-96B1-4347-AD8F-B733AF00F67FQ35917148-D7D48736-B9F2-43B3-813F-948DC4C933C5Q35920633-6068B31E-99FF-4224-B95C-6081E7BAF2B2Q36649670-CF876393-B3B5-4C24-AB25-6E0347CDDB56Q37156717-63009AC9-4AB3-4EEC-B522-32A0002967EEQ39684476-DAB13392-E5C8-4D43-AB80-8C66BC22EE9AQ39766027-62FC05B2-75EE-42D9-B400-9F281A6519B6Q40065675-7E520AF3-8D5F-4B35-9C43-29705D7DAC60Q40469287-2D9FCBF6-C4E5-4366-91D4-7D44300B87B2Q40510097-C19B65D8-5887-4768-A7F0-E906CD503C34Q43173413-719CB55D-48D9-4B15-929D-25D48CF59807Q43690728-07755F22-E0CA-440C-BB95-1A4F0C34A2EBQ44134172-F321E3EB-8095-47D6-ABCA-4BF4207368B3Q53653066-624488DB-536A-4DFB-8ACE-94C6C19C371FQ53972839-16B5CC2E-C81F-4680-A853-843DD8504FF8
P2860
Incidence and impact of resistance against approved antiretroviral drugs.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Incidence and impact of resistance against approved antiretroviral drugs.
@ast
Incidence and impact of resistance against approved antiretroviral drugs.
@en
type
label
Incidence and impact of resistance against approved antiretroviral drugs.
@ast
Incidence and impact of resistance against approved antiretroviral drugs.
@en
prefLabel
Incidence and impact of resistance against approved antiretroviral drugs.
@ast
Incidence and impact of resistance against approved antiretroviral drugs.
@en
P2093
P2860
P1476
Incidence and impact of resistance against approved antiretroviral drugs.
@en
P2093
P2860
P304
P356
10.1002/1099-1654(200007/08)10:4<231::AID-RMV290>3.0.CO;2-P
P577
2000-07-01T00:00:00Z